Breaking News Instant updates and real-time market news.

GM

General Motors

$32.53

-0.15 (-0.46%)

, GILD

Gilead

$76.21

-1.36 (-1.75%)

04:55
10/07/16
10/07
04:55
10/07/16
04:55

Salesforce to hold an expo

Dreamforce Expo 2016 is being held in San Francisco on October 4-7.

GM

General Motors

$32.53

-0.15 (-0.46%)

GILD

Gilead

$76.21

-1.36 (-1.75%)

FORR

Forrester

$38.50

-0.05 (-0.13%)

SBGSY

Schneider Electric

$14.06

0.212 (1.53%)

SPLK

Splunk

$60.20

-0.69 (-1.13%)

CRM

Salesforce

$71.26

2.84 (4.15%)

  • 23

    Oct

  • 25

    Oct

  • 06

    Nov

  • 11

    Nov

GM General Motors
$32.53

-0.15 (-0.46%)

10/06/16
GSCO
10/06/16
NO CHANGE
GSCO
Autos and Autos Parts sector downgraded to Cautious from Neutral at Goldman
Goldman analyst David Tamberrino downgraded the Autos and Auto Parts sector to Cautious from Neutral saying the US Auto cycle peaked in 2015 and is being held up by increasing OEM incentives. The analyst said OEM earnings will decline in 2017/2018 as negative pricing and lower production pressure North American results, but expects suppliers' earnings to hold up longer. The analyst sees upside to Delphi (DLPH) and Harman (HAR) given exposure to secular growth areas and upside to Goodyear Tire (GT) given secular HVA tire growth. Tamberrino downgraded Lear (LEA) to Sell citing elevated expectations and valuation, cut BorgWarner (BWA) to Neutral on valuation, downgraded Tesla (TSLA) to Neutral on execution risk and capital deployment, and upgraded AutoNation (AN) to Neutral given a more defensive business.
09/20/16
NOMU
09/20/16
INITIATION
Target $33
NOMU
Neutral
General Motors initiated with a Neutral at Nomura
Nomura analyst Anindya Das initiated General Motors with a Neutral and a $33 price target. The analyst said General Motors has significant exposure to the Chinese auto market and is concerned about pricing pressures in the market. Further, the company has yet to break even in Europe on an annual basis and its near-term prospects are clouded by Brexit uncertainties.
09/19/16
09/19/16
UPGRADE
Target $37

Overweight
General Motors upgraded to Overweight at Morgan Stanley
As previously reported, Morgan Stanley upgraded General Motors to Overweight from Equal Weight and increased its price target to $37 from $29. Analyst Adam Jonas raised near-term earnings estimates 5% above consensus and believes even flat earnings in 2017 and 2018 would be received as a positive surprise by the market. Further, the analyst said investors are underestimating how long the auto cycle can last and that General Motor's earnings and free cash flow could have a materially longer duration than the market is currently discounting. He believes investors are overlooking the time and steps needed for fully autonomous transport and said management has a healthy and realistic acceptance that it can't and should not do everything alone and will likely explore new business structures with the potential of positive values.
09/19/16
09/19/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. General Motors (GM) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Adam Jonas saying he believes even flat earnings in 2017 and 2018 would be received as a positive surprise by the market. 2. Wells Fargo (WFC) upgraded to Outperform from Neutral at Baird analyst David George saying he believes the recent pullback is a buying opportunity. 3. Lockheed Martin (LMT) upgraded to Outperform from Market Perform at Wells Fargo with analyst Sam Pearlstein saying he believes the company's earnings can grow 20% per year through 2020. 4. U.S. Steel (X), AK Steel (AKS), and Olympic Steel (ZEUS) were upgraded to Sector Weight from Underweight at KeyBanc with analyst Ivan Marcuse saying the stocks at current levels better reflect the more competitive market conditions he expects in Q4 and 2017. 5. Mattel (MAT) upgraded to Buy from Neutral at Monness Crespi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GILD Gilead
$76.21

-1.36 (-1.75%)

09/27/16
09/27/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Gilead (GILD) downgraded to Market Perform from Outperform at Leerink with analyst Geoffrey Porges saying he's now "outright bearish" on the company's Hepatitis C virus business. 2. J.M. Smucker (SJM) downgraded to Neutral from Outperform at Credit Suisse with analyst Robert Moskow saying that while the company raised its cost savings target as expected, he underestimated the hit to sales from difficult comparisons. 3. Discovery (DISCA) and Scripps Networks (SNI) downgraded to Sell from Neutral at MoffettNathanson. 4. Carter's (CRI) downgraded to Market Perform from Outperform at Wells Fargo with analyst Ike Boruchow saying his quarter-to-date store checks indicate "choppy" retail traffic trends and "deeper" pricing/promotional pressure. 5. Dollar Tree (DLTR) downgraded to Underweight from Neutral at Atlantic Equities with analyst Sam Hudson saying the second half comp inflection expected by consensus is "too demanding" and he expects multiple contraction if Family Dollar does not turn around. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/16
RBCM
10/03/16
NO CHANGE
Target $95
RBCM
Outperform
Gilead HIV franchise could see risk from competitor data, says RBC Capital
RBC Capital analyst Michael Yee said his conversations with doctors leads him to think two dolutegravir HIV "doublet" studies being conducted by GlaxoSmithKline (GSK) and ViiV Healthcare - Glaxo's joint venture with Pfizer (PFE) and Shionogi - are likely to work and present an underappreciated risk to Gilead's (GILD) HIV franchise. Talks with investors lead Yee to believe few are even aware of this risk and that the consensus view is underestimating the probability these non-inferiority trials will work. Arguing that the consensus view should factor in more conservative assumptions for Gilead's HIV business post 2018 due to this risk, Yee cut his price target on Gilead to $95 from $105, but keeps an Outperform rating on the shares.
09/27/16
LEER
09/27/16
DOWNGRADE
Target $94
LEER
Market Perform
Gilead downgraded to Market Perform from Outperform at Leerink
Leerink analyst Geoffrey Porges downgraded Gilead Sciences to Market Perform from Outperform and lowered his price target for the shares to $94 from $112. The biotech closed yesterday down 75c to $80.62. The analyst says he's now "outright bearish" on the company's Hepatitis C virus business. Gilead's HCV revenues will "decline faster, and farther," than the current consensus estimates forecast, Porges tells investors in a research note.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
FORR Forrester
$38.50

-0.05 (-0.13%)

SBGSY Schneider Electric
$14.06

0.212 (1.53%)

SPLK Splunk
$60.20

-0.69 (-1.13%)

08/26/16
NEED
08/26/16
NO CHANGE
NEED
Hold
Needham not seeing catalyst for upside to Splunk shares
Needham analyst Scott Zeller notes that Splunk's Q2 results were another "beat and raise" and says he is impressed with the growth the company is seeing in its Splunk Cloud offering. However, the analyst struggles to see an upside catalyst to shares, with decelerating revenues and billings. Zeller reiterates a Hold rating on the stock.
08/26/16
MSCO
08/26/16
NO CHANGE
MSCO
Splunk fundamentals reamin intact, says Morgan Stanley
10/04/16
GUGG
10/04/16
DOWNGRADE
GUGG
Neutral
Splunk downgraded to Neutral from Buy at Guggenheim
09/21/16
MZHO
09/21/16
INITIATION
Target $60
MZHO
Neutral
Splunk initiated with a Neutral at Mizuho
Mizuho initiated Splunk with a Neutral and a $60 price target.
CRM Salesforce
$71.26

2.84 (4.15%)

10/06/16
ROTH
10/06/16
NO CHANGE
Target $103
ROTH
Buy
Salesforce should be bought on pullback, says Roth Capital
Roth Capital analyst Richard Baldry says Salesforce's (CRM) shares are down roughly 20% from their recent highs, pressured by rumors of a potential bid for Twitter (TWTR) and a recent revenue guidance increase for the second half of 2017 that was back-end loaded enough to leave his Q3 forecast lowered. However, the analyst believes the pullback offers investors an attractive entry point and advocates buying on weakness. Baldry reiterates a Buy rating and $103 price target on Salesforce's shares given the company's strong fundamentals and sector dominance.
10/06/16
BARD
10/06/16
NO CHANGE
Target $90
BARD
Outperform
Salesforce shares should be bought, says Baird
Baird analyst Steven Ashley noted that Salesforce (CRM) CEO Mark Benioff said his company has all the customer data it needs, which he reads as meaning it would not need to make an acquisition of Twitter (TWTR) purely for data. The analyst also said the company's board is acutely aware of their responsibility to shareholders when it comes to Salesforce's stock and the potential negative impact on shares that a Twitter deal could pose. Ashley reiterated his Outperform rating and $90 price target on Salesforce shares.
10/06/16
COWN
10/06/16
NO CHANGE
Target $100
COWN
Outperform
Salesforce shares should rebound with no Twitter deal, says Cowen
Cowen analyst J.Derrick Wood expects shares of Salesforce (CRM) to rebound if the company does not buy Twitter (TWTR), which he believes will not happen. The analyst believes investors will return to fundamentals and the analyst believes upside momentum in Salesforce's core business will return in Q3. Wood reiterated his Outperform rating and $100 price target on Salesforce shares.
10/06/16
BMOC
10/06/16
NO CHANGE
BMOC
Twitter acquisition would hurt Salesforce, says BMO Capital
BMO Capital analyst Keith Bachman says that an acquisition of Twitter (TWTR) by Salesforce (CRM) would " offer little strategic fit, would slow revenue growth and would be dilutive to (free cash flow) margins." Bachman thinks that the deal would cause Salesforce's stock to drop significantly,. and he says that the company's stock would be worth $65 if it pulls the trigger on Twitter. The analyst says that Salesforce's current valuation is attractive if it does not buy Twitter. He keeps an $86 price target and Outperform rating on Salesforce.

TODAY'S FREE FLY STORIES

12:40
06/22/17
06/22
12:40
06/22/17
12:40
General news
Fed's Bullard: balance sheet unwind should start "sooner rather than later," »

Fed's Bullard:…

GE

General Electric

$27.70

-0.08 (-0.29%)

12:36
06/22/17
06/22
12:36
06/22/17
12:36
Periodicals
Nelson Peltz's Trian optimistic about GE, Flannery, CNBC reports »

Nelson Peltz's Trian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 02

    Oct

FB

Facebook

$153.91

1.66 (1.09%)

, SNAP

Snap

$17.73

0.46 (2.66%)

12:33
06/22/17
06/22
12:33
06/22/17
12:33
Periodicals
Instagram job listing signals pursuit of Hollywood ties, CNBC says »

Facebook's (FB)…

FB

Facebook

$153.91

1.66 (1.09%)

SNAP

Snap

$17.73

0.46 (2.66%)

GOOG

Alphabet

$959.45

8.82 (0.93%)

GOOGL

Alphabet Class A

$978.59

9.6 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

HCA

HCA Holdings

$87.21

3.16 (3.76%)

, LPNT

LifePoint

$64.85

0.25 (0.39%)

12:31
06/22/17
06/22
12:31
06/22/17
12:31
Hot Stocks
Hospitals, insurers rise after Republicans release draft of ACA replacement bill »

Shares of hospital and…

HCA

HCA Holdings

$87.21

3.16 (3.76%)

LPNT

LifePoint

$64.85

0.25 (0.39%)

THC

Tenet

$19.14

1.455 (8.23%)

CYH

Community Health

$9.60

0.775 (8.79%)

QHC

Quorum Health

$4.43

0.335 (8.19%)

AET

Aetna

$154.14

2.04 (1.34%)

ANTM

Anthem

$194.21

2.14 (1.11%)

CNC

Centene

$82.57

2.45 (3.06%)

CI

Cigna

$172.08

1.895 (1.11%)

HUM

Humana

$240.25

4.04 (1.71%)

MOH

Molina Healthcare

$71.57

1.84 (2.64%)

UNH

UnitedHealth

$187.73

2.81 (1.52%)

WCG

WellCare

$183.58

6.04 (3.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

TECK

Teck Resources

$16.13

0.825 (5.39%)

12:30
06/22/17
06/22
12:30
06/22/17
12:30
Options
Defensive option play in Teck Resources as shares rally »

Defensive option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$153.91

1.66 (1.09%)

12:22
06/22/17
06/22
12:22
06/22/17
12:22
Hot Stocks
Facebook holds communities event, announces new mission »

Facebook hosted its first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

FLR

Fluor

$44.29

0.52 (1.19%)

12:20
06/22/17
06/22
12:20
06/22/17
12:20
Options
Flour calls seeing opening interest »

Flour calls seeing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

12:17
06/22/17
06/22
12:17
06/22/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
06/22/17
06/22
12:16
06/22/17
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSIQ

Canadian Solar

$13.99

0.94 (7.20%)

12:10
06/22/17
06/22
12:10
06/22/17
12:10
Options
Notable call buying in Canadian Solar as shares shine »

Notable call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:10
06/22/17
06/22
12:10
06/22/17
12:10
General news
Treasury Option Action: a call 1x2 on 10s »

Treasury Option Action: a…

SRSC

Sears Canada

$0.47

-0.115 (-19.69%)

12:05
06/22/17
06/22
12:05
06/22/17
12:05
Hot Stocks
Breaking Hot Stocks news story on Sears Canada »

Sears Canada trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLSN

Nielsen

$37.08

-0.15 (-0.40%)

, GOOG

Alphabet

$959.45

8.82 (0.93%)

12:01
06/22/17
06/22
12:01
06/22/17
12:01
Hot Stocks
Nielsen launches mobile measurement for YouTube ads »

Nielsen (NLSN) announced…

NLSN

Nielsen

$37.08

-0.15 (-0.40%)

GOOG

Alphabet

$959.45

8.82 (0.93%)

GOOGL

Alphabet Class A

$978.59

9.6 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

AKS

AK Steel

$6.25

0.055 (0.89%)

12:00
06/22/17
06/22
12:00
06/22/17
12:00
Options
AK Steel Jul 8 calls are today's most active option »

AK Steel Jul 8 calls are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

CVM

CEL-SCI

$1.75

0.0576 (3.41%)

11:58
06/22/17
06/22
11:58
06/22/17
11:58
Hot Stocks
Breaking Hot Stocks news story on CEL-SCI 

Cel Sci trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAIN

Hain Celestial

$33.16

0.13 (0.39%)

11:55
06/22/17
06/22
11:55
06/22/17
11:55
Hot Stocks
Hain Celestial CEO says he has a strong management team backing him »

The Hain Celestial CEO is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 27

    Jun

HAIN

Hain Celestial

$33.16

0.13 (0.39%)

, AMZN

Amazon.com

$1,002.23

9.64 (0.97%)

11:53
06/22/17
06/22
11:53
06/22/17
11:53
Hot Stocks
Hain Celestial says Amazon deal for Whole Foods will give more exposure »

The Hain Celestial CEO is…

HAIN

Hain Celestial

$33.16

0.13 (0.39%)

AMZN

Amazon.com

$1,002.23

9.64 (0.97%)

WFM

Whole Foods

$43.26

0.48 (1.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 27

    Jun

  • 28

    Jun

SPLS

Staples

$8.66

-0.09 (-1.03%)

11:47
06/22/17
06/22
11:47
06/22/17
11:47
Recommendations
Staples analyst commentary  »

Staples intrinsic value…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMSI

Merit Medical

$36.80

-0.2 (-0.54%)

11:46
06/22/17
06/22
11:46
06/22/17
11:46
Recommendations
Merit Medical analyst commentary  »

Merit Medical allowance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

FSLR

First Solar

$37.23

1.78 (5.02%)

11:45
06/22/17
06/22
11:45
06/22/17
11:45
Options
First Solar call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

ABBV

AbbVie

$72.80

1.455 (2.04%)

11:44
06/22/17
06/22
11:44
06/22/17
11:44
Upgrade
AbbVie rating change  »

AbbVie upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMC

Commercial Metals

$18.47

0.06 (0.33%)

11:38
06/22/17
06/22
11:38
06/22/17
11:38
Hot Stocks
Breaking Hot Stocks news story on Commercial Metals »

Commercial Metals says a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

LPNT

LifePoint

$64.85

0.25 (0.39%)

, CYH

Community Health

$9.56

0.74 (8.39%)

11:35
06/22/17
06/22
11:35
06/22/17
11:35
Hot Stocks
Hosptial stocks at highs after Republicans release ACHA 'discussion draft' »

Publicly traded companies…

LPNT

LifePoint

$64.85

0.25 (0.39%)

CYH

Community Health

$9.56

0.74 (8.39%)

THC

Tenet

$18.94

1.26 (7.13%)

HCA

HCA Holdings

$87.44

3.39 (4.03%)

UHS

Universal Health

$116.28

3.06 (2.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYL

Mylan

$38.27

0.85 (2.27%)

11:26
06/22/17
06/22
11:26
06/22/17
11:26
Periodicals
Mylan investors vote against executive pay, re-elect board members, Reuters says »

Mylan shareholders voted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 13

    Jul

  • 03

    Sep

  • 09

    Oct

11:25
06/22/17
06/22
11:25
06/22/17
11:25
General news
Treasury announced an $88 B package of coupon offerings for next week »

Treasury announced an $88…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.